Hikma Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was £3,697 Mil.
During the past 12 months, Hikma Pharmaceuticals's average Total Assets Growth Rate was 2.50% per year.
During the past 3 years, the average Total Assets Growth Rate was 7.70% per year.
During the past 5 years, the average Total Assets Growth Rate was 7.30% per year.
During the past 10 years, the average Total Assets Growth Rate was 11.60% per year.
During the past 13 years, Hikma Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 60.90%. The lowest was -7.60%. And the median was 17.50%.
Hikma Pharmaceuticals Total Assets Historical Data
The historical data trend for Hikma Pharmaceuticals's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Hikma Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hikma Pharmaceuticals (LSE:HIK) Total Assets Explanation
Note:
The Net Income data used here is two times the semi-annual (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Hikma Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Hikma Pharmaceuticals Total Assets Related Terms
Thank you for viewing the detailed overview of Hikma Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Hikma Pharmaceuticals (LSE:HIK) Business Description
Hikma Pharmaceuticals PLC is engaged in the development, manufacture, and marketing of a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the company's sales are based in the U.S. and to a lesser degree in the Middle East, North Africa, and Europe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LSE:HIK has been successfully added to your 